ICPTSep 11, 20250.00% since signalIntercept Pharma withdraws liver disease drug from US marketIntercept voluntarily withdraws liver treatment from U.S. market due to FDA request. This action significantly impacts ICPT’s market position and future revenue prospects.View signal analysis →
ICPTDec 12, 20240.00% since signalUS FDA says Intercept's drug can cause liver injury in patients without scarringFDA warns Intercept's liver drug may cause organ injury in specific patients.View signal analysis →